Parkinson’s disease is a complex condition that primarily affects the brain and leads to a range of symptoms. In some people with Parkinson’s disease, LRRK2 (short for leucine-rich repeat kinase 2) is known to play a key role. Even if you don’t have a family history of Parkinson’s disease, LRRK2 may still be involved. When the LRRK2 pathway is overactive, it can lead to damage in the brain that causes Parkinson’s disease symptoms.

Neuron23 is conducting NEULARK, an innovative clinical trial design for people with Parkinson’s disease. The study will evaluate the safety and efficacy of NEU-411, an investigational treatment for a genetically-defined subset of people with Parkinson’s disease. NEU-411 is taken orally and is designed to inhibit LRRK2 overactivity. This study design uses new technologies to track the symptoms and disease progression of participants, while minimizing the burden of participating in a clinical trial.